IP Library Granted Patent US 46,745
Granted Patent E1
US 46,745 · App. 14/567,942 · Granted Mar 6, 2018

Recombinant cell clones having increased stability and methods of making and using the same

Inventors: Manfred Reiter (Vienna, AT); Wolfgang Mundt (Vienna, AT); Friedrich Dorner (Vienna, AT)
Assignees: Baxalta Incorporated; Baxalta GmbH
C12N5/0075C12N5/0043C12N2500/32C12N2500/46C12N2500/50C12N2500/76C12N2531/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 46,745
App. No.
14/567,942
Granted
Mar 6, 2018
Kind
E1
Abstract

Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.

Claims (23)

1. A method for obtaining a an isolated stable recombinant mammalian cell clone that produces a recombinant product and is stable under production conditions in serum- and protein-free medium for at least 40 generations, the method comprising:

providing a recombinant original mammalian cell clone, wherein the recombinant original mammalian cell clone has a selection marker and an amplification marker,

cultivating the recombinant original cell clone on serum-containing medium,

adapting the cells to serum- and protein-free medium with neither without selection pressure for the selection marker nor selection for a polypeptide factor that replaces serum components,

testing the cell culture after adaptation for stable product-producers with neither without selection pressure for the selection marker nor selection for a polypeptide factor that replaces serum components, and

cloning isolating a stable product-producer-cell clone in serum- and protein-free conditions with neither without selection pressure for the selection marker nor selection for a polypeptide factor that replaces serum components.

2. The method according to claim 1 , wherein the stable product-producer cell clone obtained is present in isolated form after the step of cloning.

3. The method according to claim 1 , wherein the recombinant cell clone comprises a nucleic acid encoding a recombinant polypeptide or protein.

4. The method according to claim 1 , wherein the recombinant product is Factor VIII.

5. The method according to claim 1 , wherein the recombinant product is Factor IX.

6. The method according to claim 1 , wherein the recombinant product is Factor VII.

7. The method according to claim 1 , wherein the recombinant product is von Willebrand factor (vWF).

8. The method according to claim 1 , wherein the original mammalian cell clone is a CHO cell clone.

9. A method for preparing a recombinant protein, the method comprising:

culturing the stable recombinant mammalian cell clone obtained by the method of claim 1 and expressing the recombinant protein in serum- and protein-free media so as to obtain a cell culture; and

recovering the expressed recombinant protein from the cell culture.

10. The method according to claim 9, wherein the recombinant protein is Factor VIII.

11. The method according to claim 9, wherein the recombinant protein is Factor IX.

12. The method according to claim 9, wherein the recombinant protein is Factor VII.

13. The method according to claim 9, wherein the recombinant protein is von Willebrand factor (vWF).

14. The method according to claim 9, wherein the original mammalian cell clone is a CHO cell clone.

15. The method according to claim 9, wherein the serum- and protein-free media comprises one or more amino acids selected from the group consisting of: L-asparagine, L-cysteine, L-cystine, L-proline, L-tryptophan and L-glutamine.

16. The method according to claim 9, wherein the serum- and protein free media comprises soybean peptone having a molecular weight of ≦1000 Dalton.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 040231/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: BAXTER INNOVATIONS GMBH
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 040567/0848 →
CHANGE OF NAME Recorded Nov 4, 2016
From: BAXTER AKTIENGESELLSCHAFT
To: BAXTER EASTERN EUROPE VERTRIEBS GMBH
Reel/Frame 040569/0383 →
CHANGE OF NAME Recorded Nov 4, 2016
From: BAXTER EASTERN EUROPE VERTRIEBS GMBH
To: BAXTER TRADING GMBH
Reel/Frame 040569/0387 →
CHANGE OF NAME Recorded Nov 4, 2016
From: BAXTER TRADING GMBH
To: BAXTER INNOVATIONS GMBH
Reel/Frame 040569/0391 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2016
From: REITER, MANFRED; MUNDT, WOLFGANG; DORNER, FRIEDRICH
To: BAXTER AKTIENGESELLSCHAFT
Reel/Frame 040155/0171 →
Priority Claims (1)
AT 1073/97 · Jun 20, 1997 · national
Continuity (7)
Reissue 12986111 · Jan 6, 2011
Continuation 12488441 · Jun 19, 2009
Continuation 11482504 · Jul 7, 2006
Division 11123362 · May 6, 2005
Continuation 10170661 · Jun 12, 2002
Continuation 09324612 · Jun 2, 1999
Continuation In Part 09100253 · Jun 19, 1998